AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 7983-7991

  Lee, Ying En ^a   He, Hong Lin ^b   Lee, Sung Wei ^c   Chen, Tzu Ju ^c   Chang, Kwang Yu ^d   Hsing, Chung Hsi ^c   Li, Chien Feng ^c,d,e,f  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

AMACR; Nasopharyngeal carcinoma; Prognosis; Transcriptome

Indexed keywords

ALPHA-METHYLACYL-COA RACEMASE; ISOMERASE;

ADULT; AGED; CANCER STAGING; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RACEMASES AND EPIMERASES; RETROSPECTIVE STUDIES;

EID: 84922391424     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2065-z     Document Type: Article

References (48)

1. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell. 2004;5:423–8.
2. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev. 2006;15:1765–77.
3. Jeyakumar A, Brickman TM, Jeyakumar A, Doerr T. Review of nasopharyngeal carcinoma. Ear Nose Throat J. 2006;85:168–70. 172-163, 184.
4. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:230–4.
5. Lloyd MD, Darley DJ, Wierzbicki AS, Threadgill MD. Alpha-methylacyl-coa racemase—an ‘obscure’ metabolic enzyme takes centre stage. FEBS J. 2008;275:1089–102.
6. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. Alpha-methylacyl-coa racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62:2220–6.
7. Allory Y, Bazille C, Vieillefond A, Molinie V, Cochand-Priollet B, Cussenot O, et al. Profiling and classification tree applied to renal epithelial tumours. Histopathology. 2008;52:158–66.
8. Dorer R, Odze RD. Amacr immunostaining is useful in detecting dysplastic epithelium in barrett’s esophagus, ulcerative colitis, and crohn’s disease. Am J Surg Pathol. 2006;30:871–7.
9. Gunia S, May M, Scholmann K, Storkel S, Hoschke B, Koch S, et al. Expression of alpha-methylacyl-coa racemase correlates with histopathologic grading in noninvasive bladder cancer. Virchows Archiv. 2008;453:165–70.
10. Lee WA. Alpha-methylacyl-coa-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach. Oncology. 2006;71:246–50.
11. Sonwalkar SA, Rotimi O, Scott N, Verghese E, Dixon M, Axon AT, et al. A study of indefinite for dysplasia in barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with amacr (alpha-methylacyl-coa-racemase). Histopathology. 2010;56:900–7.
12. Zhang X, Leav I, Revelo MP, Deka R, Medvedovic M, Jiang Z, et al. Deletion hotspots in amacr promoter cpg island are cis-regulatory elements controlling the gene expression in the colon. PLoS Genet. 2009;5:1–15.
13. Sengupta S, den Boon JA, Chen IH, Newton MA, Dahl DB, Chen M, et al. Genome-wide expression profiling reveals ebv-associated inhibition of mhc class i expression in nasopharyngeal carcinoma. Cancer Res. 2006;66:7999–8006.
14. Ma LJ, Lee SW, Lin LC, Chen TJ, Chang IW, Hsu HP, et al. Fibronectin overexpression is associated with latent membrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma. Tumour Biol. 2014;35:1703–12.
15. Lan J, Tai HC, Lee SW, Chen TJ, Huang HY, Li CF. Deficiency in expression and epigenetic DNA methylation of ass1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance. Tumour Biol. 2014;35:161–9.
16. Lan J, Huang HY, Lee SW, Chen TJ, Tai HC, Hsu HP, et al. Top2a overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma. Tumour Biol. 2014;35:179–87.
17. Hsu HP, Li CF, Lee SW, Wu WR, Chen TJ, Chang KY, et al. Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma. Tumour Biol. 2014;35:2619–29.
18. Win KT, Lee SW, Huang HY, Lin LC, Lin CY, Hsing CH, et al. Nicotinamide n-methyltransferase overexpression is associated with akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma. Tumour Biol. 2013;34:3923–31.
19. Lee SW, Chen TJ, Lin LC, Li CF, Chen LT, Hsing CH, et al. Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma. Exp Mol Pathol. 2013;95:83–90.
20. Bames LEJ, Relchart P, Sidransky D, editors. Pathology and genetics of head and neck tumors. Lyon: IARCP Press; 2005.
21. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. Heidelberg: Springer; 2010.
22. Wolden SL, Zelefsky MJ, Kraus DH, Rosenzweig KE, Chong LM, Shaha AR, et al. Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:1105–10.
23. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase iii study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631–7.
24. Chang SE, Foster S, Betts D, Marnock WE. Dok, a cell line established from human dysplastic oral mucosa, shows a partially transformed non-malignant phenotype. Int J Cancer. 1992;52:896–902.
25. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, et al. Two epithelial tumor cell lines (hne-1 and hone-1) latently infected with epstein-barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci U S A. 1989;86:9524–8.
26. Lin CT, Wong CI, Chan WY, Tzung KW, Ho JK, Hsu MM, et al. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Investig. 1990;62:713–24.
27. Wu LC, Chen LT, Tsai YJ, Lin CM, Lin CY, Tian YF, et al. Alpha-methylacyl coenzyme a racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator. J Clin Pathol. 2012;65:309–14.
28. Jiang Z, Woda BA, Wu CL, Yang XJ. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl coa racemase (p504s). Am J Clin Pathol. 2004;122:275–89.
29. Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M. Messenger rna expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res. 2005;11:6558–66.
30. Jiang Z, Fanger GR, Banner BF, Woda BA, Algate P, Dresser K, et al. A dietary enzyme: alpha-methylacyl-coa racemase/p504s is overexpressed in colon carcinoma. Cancer Detect Prev. 2003;27:422–6.
31. Witkiewicz AK, Varambally S, Shen R, Mehra R, Sabel MS, Ghosh D, et al. Alpha-methylacyl-coa racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. Cancer Epidemiol Biomark Prev. 2005;14:1418–23.
32. Kao YC, Lee SW, Lin LC, Chen LT, Hsing CH, Hsu HP, et al. Fatty acid synthase overexpression confers an independent prognosticator and associates with radiation resistance in nasopharyngeal carcinoma. Tumour Biol. 2013;34:759–68.
33. Chen W, Wu W, Zhao J, Yu C, Liu W, Jiang A, et al. Molecular cloning and preliminary analysis of the human alpha-methylacyl-coa racemase promoter. Mol Biol Rep. 2009;36:423–30.
34. Daugherty SE, Platz EA, Shugart YY, Fallin MD, Isaacs WB, Chatterjee N, et al. Variants in the alpha-methylacyl-coa racemase gene and the association with advanced distal colorectal adenoma. Cancer Epidemiol Biomark Prev. 2007;16:1536–42.
35. Wright JL, Neuhouser ML, Lin DW, Kwon EM, Feng Z, Ostrander EA, et al. Amacr polymorphisms, dietary intake of red meat and dairy and prostate cancer risk. Prostate. 2011;71:498–506.
36. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, et al. Alpha-methylacyl-coa racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res. 2003;63:7365–76.
37. Ouyang B, Leung YK, Wang V, Chung E, Levin L, Bracken B, et al. Alpha-methylacyl-coa racemase spliced variants and their expression in normal and malignant prostate tissues. Urology. 2011;77:249.e241–247.
38. Clayton PT. Clinical consequences of defects in peroxisomal beta-oxidation. Biochem Soc Trans. 2001;29:298–305.
39. Ferdinandusse S, Denis S, Clayton PT, Graham A, Rees JE, Allen JT, et al. Mutations in the gene encoding peroxisomal alpha-methylacyl-coa racemase cause adult-onset sensory motor neuropathy. Nat Genet. 2000;24:188–91.
40. Savolainen K, Kotti TJ, Schmitz W, Savolainen TI, Sormunen RT, Ilves M, et al. A mouse model for alpha-methylacyl-coa racemase deficiency: adjustment of bile acid synthesis and intolerance to dietary methyl-branched lipids. Hum Mol Genet. 2004;13:955–65.
41. Carnell AJ, Hale I, Denis S, Wanders RJ, Isaacs WB, Wilson BA, et al. Design, synthesis, and in vitro testing of alpha-methylacyl-coa racemase inhibitors. J Med Chem. 2007;50:2700–7.
42. Wilson BA, Wang H, Nacev BA, Mease RC, Liu JO, Pomper MG, et al. High-throughput screen identifies novel inhibitors of cancer biomarker alpha-methylacyl coenzyme a racemase (amacr/p504s). Mol Cancer Ther. 2011;10:825–38.
43. Woodman TJ, Wood PJ, Thompson AS, Hutchings TJ, Steel GR, Jiao P, et al. Chiral inversion of 2-arylpropionyl-coa esters by human alpha-methylacyl-coa racemase 1a (p504s)—a potential mechanism for the anti-cancer effects of ibuprofen. Chem Commun (Camb). 2011;47:7332–4.
44. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42:73–8.
45. Oshio H, Abe T, Onogawa T, Ohtsuka H, Sato T, Ii T, et al. Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines. J Gastroenterol. 2008;43:538–49.
46. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993;90:11693–7.
47. Lloyd MD, Yevglevskis M, Lee GL, Wood PJ, Threadgill MD, Woodman TJ. Alpha-methylacyl-coa racemase (amacr): metabolic enzyme, drug metabolizer and cancer marker p504s. Prog Lipid Res. 2013;52:220–30.
48. Johnson CC, Hayes RB, Schoen RE, Gunter MJ, Huang WY. Non-steroidal anti-inflammatory drug use and colorectal polyps in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Gastroenterol. 2010;105:2646–55.